AbbVie's Etentamig Hits Primary Endpoints in Phase 3 Myeloma Trial
ABBV sits 37% above its 52-week low of $190.75 on light trading volume (0.2× avg).
Summary
AbbVie's investigational bispecific antibody etentamig met its primary endpoints in the Phase 3 CERVINO trial for relapsed/refractory multiple myeloma, showing a 74% objective response rate versus 45.7% for standard therapy and significantly improved progression-free survival. The 12-month overall survival rate was 87.9% versus 72%, though the OS data have not yet crossed the prespecified efficacy boundary. Safety was manageable with lower fatal infections and fewer discontinuations than standard care. The Independent Data Monitoring Committee recommended unblinding, and AbbVie will engage global regulators on next steps. This is a major pipeline catalyst for AbbVie's oncology franchise, which has been overshadowed by immunology growth from Skyrizi and Rinvoq. The company recently completed a $10 billion bond offering to fund its Apogee Therapeutics acquisition, and this positive data strengthens its long-term growth outlook beyond Humira.
At the time of this announcement, ABBV was trading at $260.74 on NYSE in the Life Sciences sector, with a market capitalization of approximately $460.8B. The 52-week trading range was $190.75 to $267.47. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Benzinga.